Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 9
Submit an article Journal homepage
279
Views
162
CrossRef citations to date
0
Altmetric
Miscellaneous

Combretastatin A4 phosphate: background and current clinical status

Scott L Young OXiGENE, Inc., 230 Third Avenue, Waltham, MA 02451, USA. [email protected]
&
David J Chaplin OXiGENE, Inc., 230 Third Avenue, Waltham, MA 02451, USA. [email protected]
Pages 1171-1182 | Published online: 24 Feb 2005

Bibliography

  • PETTIT GR, CRAGG GM, SINGH SB: agents, 122. Constituents of Combreturn caffrum. I. Nat. Prod (1987) 50(3):386–391.
  • •Details of the isolation of combretastatins from Combretum caffrum.
  • PETTIT GR, SINGH SB, HAMEL E, LIN CM et al.: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia (1989) 45(2):209–211.
  • LIN CM, SINGH SB, CHU PS, RO et al: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. (1988) 34(2):200–208.
  • LUDFORD RI, Factors determining the action of colchicine on tumour growth. Br. J. Cancer (1948) 2:75–86.
  • BAGULEY BC, HOLDAWAY KM, THOMSEN LL, ZHUANG L et al: Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer (1991) 27(4):482–487.
  • BOYLAND E, BOYLAND ME: Studies in tissue metabolism. IX The action of colchicine and B typhosus extract. Biochent. J. (1937) 31:454–460.
  • DARK GG, HILL SA, PRISE VE, TOZER GM et al.: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. (1997) 57(10):1829–1834.
  • •Initial work determining the vascular disrupting activity of CA4P.
  • TOZER GM, PRISE VE, WILSON J, RI et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. (1999) 59(7):1626–1634.
  • •This paper shows the selective blood flow shutdown seen in tumor compared with normal tissues.
  • BLAKEY DC, WESTWOOD FR, WALKER M, HUGHES GD et al: Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models. (-Matra] Cancer Res. (2002) 8(6):1974–1983.
  • HORI K, SAITO S, NIHEI Y, SUZUKI M et al.: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. fpn J. Cancer Res. (1999) 90(9):1026–1038.
  • HORI K, SAITO S, KUBOTA K: A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br. J. Cancer (2002) 86(10):1604–1614.
  • GALBRAITH SM, CHAPLIN DJ, LEE F, STRATFORD MR et al: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. (2001) 21(1A)93–102.
  • •This paper decribes the effects of CA4P on endothelial cell shape in proliferating versus quiescent cells. The time course of the effect mirrors that of the blood flow shutdown seen in vivo.
  • CHAPLIN DJ, DOUGHERTY GJ: Tumour vasculature as a target for cancer therapy. Br. J. Cancer (1999) 80(Suppl.):57–64.
  • TOZER GM, KANTHOU C, CS, HILL SA: The biology of the combretastatins as vascular targeting agents. Int. J. Exp. Pathol (2002) 83(1):21–38.
  • PETTIT GR, TEMPLE C Jr, NARAYANAN VL, VARMA R et al.: Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. (1995) 10(4):299–309.
  • PETTIT GR, RHODES MR: agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des. (1998) 13(3):183–191.
  • WOODS JA, HADFIELD JA, PETTIT GR, FOX BW et al.: The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer (1995) 71(4):705–711.
  • LIN CM, HO HH, PETTIT GR, HAMEL E: Antimitotic natural products combretastatin A-4 and combretastatin A: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry (1989) 28(17):6984–6991.
  • DZIBA JM, MARCINEK R, G, ROBINSON JA et al.: Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid (2002) 12(12):1063–1070.
  • BOEHLE AS, SIPOS B, KLICHE U, KALTHOFF H et al.: Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine model. Ann. Thorac. Surg. (2001) 71(5):1657–1665.
  • EL-ZAYAT AA, DEGEN D, DRABEK S, CLARK GM et al: In vitroevaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs (1993) 4(1):19–25.
  • BOHLE AS, LEUSCHNER I, KALTHOFF H, HENNE-BRUNS D: Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int. J. Cancer (2000) 87(6):838–843.
  • GROSIOS K, HOLWELL SE, AT, PETTIT GR et al: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. Cancer (1999) 81(8):1318–1327.
  • BEAUREGARD DA, THELWALL PE, CHAPLIN DJ, HILL SA et al.: Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br. J. Cancer (1998) 77(11):1761–1767.
  • EIKESDAL HP, SCHEM BC, MELLA 0, DAHL 0: The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int. J. Radiat. Oncol Biol. Phys. (2000) 46(3):645–652.
  • HORSMAN MR, EHRNROOTH E, LADEKARL M, OVERGAARD J: The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. mt. J. Radiat. Oncol Biol. Phys. (1998) 42(4):895–898.
  • MAXWELL RJ, NIELSEN FU, BREIDAHL T, STODKILDE-JORGENSEN H et al: Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. Int. I Radiat. Oncol Biol. Phys. (1998) 42(4):891–894.
  • CHAPLIN DJ, PETTIT GR, HILL SA: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. (1999) 19(14189–195.
  • CHAPLIN DJ, HORSMAN MR: The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiothec Oncol (1994) 30(1):59–65.
  • •This paper shows that extensive tumour cell kill occurs in vivo within a few hours of shutting off the blood supply.
  • LI L, ROJIANI A, SIEMANN DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int. j Radiat. Oncol Biol. Phys. (1998) 42(4):899–903.
  • SIEMANN DW, MERCER E, LEPLER S, ROJIANI AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer (2002) 99(1):1–6.
  • •Shows that CA4P enhances the antitumor action of chemotherapeutic agents in animal models.
  • CHAPLIN DJ, HILL SA: The development combretastatin A4 phosphate as a targeting agent. Int. .1. Radiat. Oncol Biol. Phys. (2002) 54(5):1491–1496.
  • ••Review detailing the development andmechanism of action of CA4P.
  • CHAPLIN DJ, HORSMAN MR, TROTTER MJ, SIEMANN DW: Therapeutic significance of microenvironmental factors. In: Medical Radiology Diagnostic Imaging, and Radiation Oncology Blood perfusion and microenvironment of human tumors. M Molls, P Vaupel (Eds), Springer-Verlag, Berlin, Germany (1998):133–143.
  • HORSMAN MR, MURATA R, BREIDAHL T, NIELSEN FU et al.: Combretastatins: novel vascular targeting drugs for improving anti- cancer therapy. Combretastatins and conventional therapy. Adv. Exp. Med. Biol. (2000) 476:311–323.
  • LANDUYT W, AHMED B, NUYTS S, THEYS J et al.: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int. I Radiat. Oncol Biol. Phys. (2001) 49(2):443–450.
  • HORSMAN MR, R MURATA: Combination of vascular targeting agents with thermal or radiation therapy. Int. J. Radiat. Oncol Biol. Phys. (2002) 54(5):1518–1523.
  • PEDLEY RB, HILL SA, BOXER GM, FLYNN AA et al.: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-0-phosphate. Cancer Res. (2001) 61(12):4716–4722.
  • GROSIOS K, LOADMAN PM, SWAINE DJ, PETTIT GR et al.: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine adenocarcinoma. Anticancer Res. (2000) 20(1A):229–233.
  • NELKIN BD, BALL DW: Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep (2001) 8(1):157–160.
  • WILDIERS H, AHMED B, GUETENS G, DE BOECK G et al.: Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Ear: Cancer (2004) 40(2):284–290.
  • MURATA R, SIEMANN DW, OVERGAARD J, HORSMAN MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiothec Oncol (2001) 60(2):155–161.
  • MURATA R, OVERGAARD J, HORSMAN MR: Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int. Radiat. Oncol Biol. Phys. (2001) 51(4):1018–1024.
  • HORSMAN MR, CHRISTENSEN KL, OVERGAARD J: Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int. .1. Hyperthermia (1989) 5(2):123–136.
  • EIKESDAL HP, BJERKVIG R, MELLA 0, DAHL 0: Combretastatin A-4 and hyperthermia,a potent combination for the treatment of solid tumors. Radiothec Oncol (2001) 60(2):147–154.
  • GRIGGS J, HESKETH R, SMITH GA, BRINDLE KM et al.: Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br. Cancer (2001) 84(6):832–835.
  • GRIGGS J, SKEPPER JN, SMITH GA, BRINDLE KM et al.: Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am. Pathol (2002) 160(3) :1097–1103.
  • NAMBU H, NAMBU R, MELIA M, CAMP OCHIARO PA: Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol Vis. Sci. (2003) 44(8):3650–3655.
  • ••This paper shows that CA4P can induceregression of abnormal blood vessels in a mouse model of corneal neovascularisation.
  • STRATFORD MR, DENNIS MF: Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography. Chromatogr. B. Biomed. Sci. Appl. (1999) 721(1):77–85.
  • DOWLATI A, ROBERTSON K, COONEY M, PETROS WP et al: A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. (2002) 62(12):3408–3416.
  • STEVENSON JP, ROSEN M, SUN W, GALLAGHER M et al: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. Jan. Oncol (2003) 21(23):4428–4438.
  • RUSTIN GJ, GALBRAITH SM, ANDERSON H, STRATFORD M et al: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol (2003) 21(15):2815–2822.
  • •The Phase I study of CA4P administered on a once-weekly schedule establishes a MTD of 68 mg/m2. This is the schedule most widely used in the current ongoing trials.
  • GALBRAITH SM, MAXWELL RJ, LODGE MA, TOZER GM et al: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. JClin. Oncol (2003) 21(15):2831–2842. demonstrates the ability of CA4P to shutdown tumour blood flow in the clinic.
  • ANDERSON HL, YAP JT, MILLER MP, ROBBINS A et al: Assessment of pharmacodynamic vascular response in a Phase I trial of combretastatin A4 phosphate. Clin. Oncol (2003) 21(15):2823–2830.
  • HUE, KO R, KODA R, ROSEN Pet al: Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemothec Pharmacol (1990) 26(5):359–364.
  • SIFTON D, MURRAY L, KELLY G: Physicians' Desk Reference (55th Edition). Medical Economics Company, Inc., Montvale NJ, USA (2001).
  • PLATTS SH, FAL CONE JC, WT, HILL MA et al.: Alteration of microtubule polymerization modulates arteriolar vasomotor tone. Am. J. Physiol (1999) 277(1 Pt 2): H100–106.
  • BAZETT HC: An analysis of the time-relations of electrocardiograms. Heart (1920) 7:353–367.
  • FRIDERICIA LS: Die Systolendauer im Electrokardiogramm bei normalen Menchan und bei Herzdranken. Acta Med. Scand. (1920) 53:469–486.
  • HONESS DJ, HYLANDS F, DJ, TOZER GM: Comparison of strategies to over come the hypertensive effect of Combretastatin A4 phosphate in a rat model. Br: J. Cancer (2002) 86 S166. 278.

Websites

  • http://www.astrazeneca-us.com Toprol-XL product information.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.